Binding Site’s Immunologicals Group has completed a major expansion to their monoclonal antibody product offerings. In addition to the established conjugated and unconjugated versions of the IgG4 Clone-HP6025 and the CD23 Clone BU-3438, the company recently introduced a number of new monolclonals focused on infectious diseases, including CMV, Hepatitis (A, B, C, and D), Herpes, HIV, Rubella, and Toxoplasma.
All of these antibodies exhibit degrees of specificity, while demonstrating high levels of purity, extended shelf-life stability claims, and lot-to-lot consistencies. The infectious disease monoclonal antibodies are all available in a standard-sized 1.0 mg fill format, while the rest come in a standard 0.2mg fill format. Plus, bulk packaging and customer-specific packaging options are for all available for all of these monoclonal antibodies.